Tags : Psilocybin Therapy

Compass Pathways’ Psilocybin Therapy Receives FDA’s Breakthrough Therapy Designation for

Shots: The FDA’s BT designation follows clinical study assessing Psilocybin in 19 patients with treatment resistant depression, conducted at Imperial College London in 2015 FDA’s BT designation is granted to the drugs showing substantial improvement over currently available therapy in serious or life-threatening conditions on at least one clinically significant endpoint with benefits of Priority […]Read More